Verastem, Inc. (VSTM)

Oncology Corporate Profile

Stock Performance

5.1150
0.0750

3 Month Stock History Chart

Data provided for free by IEX.

HQ Location

215 First Street, Suite 440
Cambridge, MA 2142

Company Description

Verastem, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation.

Website: http://www.verastem.com

Brand Generic Indication
Copiktra™duvelisibCopiktra™ is a kinase inhibitor indicated for the treatment of adult patients with:
-Relapsed or refractory chronic lymphocytic leukemia (CLL) or small
lymphocytic lymphoma (SLL) after at least two prior therapies.
-Relapsed or refractory follicular lymphoma (FL) after at least two prior
systemic therapies. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
duvelisibP13K inhibitorChronic Lymphocytic Leukemia (CLL)III
defactinibP13K inhibitorChronic Lymphocytic Leukemia (CLL)II
duvelisibP13K inhibitorDouble-Refractory Follicular Lymphoma (FL)II
defactinib (+ pembrolizumab)P13K inhibitorMesotheliomaIIMerck
defactinib (+ pembrolizumab)P13K inhibitorNon Small Cell Lung Cancer (NSCLC)IIMerck
duvelisibP13K inhibitorNon-Hodgkin's Lymphoma (NHL)II
defactinib (+ avelumab)P13K inhibitorOvarian cancerIIPfizer and Merck
defactinib (+ pembrolizumab)P13K inhibitorPancreatic cancerIIMerck
duvelisibP13K inhibitorSmall Lymphocytic Lymphoma (SLL)II
defactinib (+ pembrolizumab and gemcitabine)P13K inhibitorPancreatic cancerIMerck
duvelisibP13K inhibitorRefractory T-cell LymphomaI
VS-5584mTORC1/2 inhibitorLymphomaPreclinical
VS-4718 (+ abraxane)FAK/PYK2 inhibitorPancreatic cancerPreclinical
VS-5584mTORC1/2 inhibitorVarious cancer typesPreclinical
VS-4718 (+ abraxane)FAK/PYK2 inhibitorVarious cancer typesPreclinical

Source: http://www.verastem.com

Recent News Headlines

8/21/2017 06:23 am

8/21/2017 06:23 am

8/21/2017 06:23 am

8/21/2017 06:23 am

8/21/2017 06:23 am

8/18/2017 06:20 am

8/18/2017 06:20 am

8/18/2017 06:20 am

8/14/2017 06:20 pm

8/14/2017 06:20 pm

8/14/2017 06:20 pm

8/8/2017 12:20 pm

8/8/2017 12:20 pm

8/8/2017 12:20 pm

8/8/2017 12:20 pm

8/8/2017 06:20 am

7/25/2017 12:35 am

7/25/2017 12:35 am

7/13/2017 06:20 am

7/11/2017 12:20 pm

7/7/2017 06:20 am

6/24/2017 06:20 am

6/7/2017 12:19 pm

6/5/2017 12:20 pm

5/10/2017 12:19 pm